search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


FATLOSE trial: Fecal Administration To LOSE weight.


- candidate number5651
- NTR NumberNTR1776
- ISRCTNISRCTN wordt niet meer aangevraagd
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR24-apr-2009
- Secondary IDs17378 CCMO
- Public TitleFATLOSE trial: Fecal Administration To LOSE weight.
- Scientific TitleTreatment of overweight and insulin resistance by fecal enema harvested from lean volunteers in patients with metabolic syndrome; the FATLOSE trial.
- ACRONYMFATLOSE trial
- hypothesisHypothesis: infusion of lean donor feces in obese subjects is effective on weight reduction, systemic inflammatory pathways and insulin resistance.
- Healt Condition(s) or Problem(s) studiedMetabolic syndrome
- Inclusion criteria1. Male obese subjects with metabolic syndrome ( at least 3 out of 5 NCEP metabolic syndrome criteria);
2. 21-65 yr.
- Exclusion criteria1. Cardiovascular event;
2. Diabetic kidney failure;
3. Prolonged compromised immunity;
4. Antidiabetic medicine;
5. Lipid lowering medicine.
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingDouble
- controlPlacebo
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-jan-2009
- planned closingdate1-jan-2011
- Target number of participants20
- Interventions1. Arm 1: allogenic fecal therapy (donor feces from lean volunteer);
2. Arm 2: autologic fecal therapy (patients' own feces).
- Primary outcome1. Fecal flora composition;
2. Weight.
- Secondary outcome1. Insulin resistance;
2. Biochemical parameters;
3. Inflammatory parameters;
4. Gut epithelium (duodenal and jejunal mucosal biopsies).
- Timepoints1. Baseline;
2. 2days;
3. 2 weeks;
4. 6 weeks;
5. 12 weeks.
- Trial web siteN/A
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIESDrs. A. Vrieze
- CONTACT for SCIENTIFIC QUERIESDrs. A. Vrieze
- Sponsor/Initiator Academic Medical Center (AMC), Amsterdam
- Funding
(Source(s) of Monetary or Material Support)
Academic Medical Center (AMC)
- PublicationsN/A
- Brief summaryRecent research shows that obesity is associated with changed bowel flora composition with a relative abundance of the two dominant bacterial divisions, the Bacteroidetes and the Firmicutes. Interestingly, this specific bacteria associated condition is transmissible: colonization of obese mice with an ‘leanmicrobiota’ results in a significantly greater decrease in total body fat than colonization with a ‘obese microbiota. In addition, Bacteroidetes species are decreased and Firmicutes increased in feces of obese people compared to lean people. Moreover weight correlated with percentage loss of body weight in obese subjects. Changing fecal flora composition in overweight MS patients might therefore be total novel and effective prevention of the rapid increase patients with type 2 diabetes, that is needed so urgently. This trial is performed which infusion of lean donor feces through a duodenal tube, compared with autologic (patients own feces) transplantation. Endpoints are changes in faecal flora, weight, insulin resistance and systhemic/biochemical parameters. Folluw up is 12 weeks
- Main changes (audit trail)
- RECORD24-apr-2009 - 23-sep-2009


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl